0: Evaluation of compounds for anti-proliferative activity against the breast cancer cell lines BT-474, MCF-10A, and MDA-MB-231 and pancreatic cell lines Bx-PC-3, Panc-1, and Su-86-86 was undertaken as described in detail by Lovitt et al.
1: [ 23].
